AstraZeneca: Lost Stock or Cheap Turnaround?

AstraZeneca may pay a heft dividend, but the company has been facing a number of headwinds and regulatory setbacks lately. In the following video from the Motley Fool's health-care show, Market Checkup, analysts David Williamson and Max Macaluso discuss the partnerships that this company has been forming to boost its pipeline and the key to accelerating its turnaround.

9 rock-solid dividends
One of the best parts of owning big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.

The article AstraZeneca: Lost Stock or Cheap Turnaround? originally appeared on Fool.com.

David Williamson and Max Macaluso, Ph.D. have no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.